Skip to content

Divi’s Laboratories Q4 profit rises 13%, beating estimates; margin slips

The board of the Hyderabad-based pharmaceutical company also recommended a final dividend of ₹30 per share for FY26.​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *